



INVEST IN ONE HEALTH BIOSENSING

**AI enabled, ultra-low cost, and pain-free, needle-free - We didn't invent CGM, we just redefined it**

[onehealthbiosensing.com](https://onehealthbiosensing.com) New York, NY



## Highlights

- 1 A multi-modal AI-enabled health sensing platform designed to revolutionize the \$10bn CGM market
- 2 A low-cost, painless, needle-free solution for >1Bn people with diabetes, pre-diabetes and obesity

- 3 Proprietary silicon micro-needle array technology, 10 years in R&D, protected by >50 issued patents
- 4 Demonstrated performance in >1,500 hrs of onbody clinical data with an estimated MARD of <10
- 5 Bolstered by >60Bn data points and AI capabilities proven to reduce A1C by 1.9% and weight by >10lbs
- 6 Projecting \$250M in revenue two years post launch and >\$1bn five years post launch (not guaranteed)
- 7 Founder and CEO with a proven track record of successful exits and a world class leadership team
- 8 Existing investors include RRE, Box Group, FJ Labs, True Ventures, First Round Capital, and others

## Featured Investors



**Craig Kanarick**   
Syndicate Lead

Follow

Invested \$5,000 

Craig is the CEO of New York Cruise Lines, a marine-based sightseeing, entertainment and transportation business based in NYC.

“The market for CGM is expected to be explosive and expand rapidly as people start to monitor their blood glucose to manage diabetes, weight, and health. The AI-enabled, ultra-low cost, pain free, flexible One Health CGM is exactly what the market and payers want to keep people healthy. Today the 2 existing CGM players (Abbott and Dexcom) have products engineered for intensive insulin users and are high cost to payers. With One Health, people with Type 2 diabetes not on insulin, people on GLP-

1s, people trying to lose weight, and people interested in monitoring their health will have affordable access to CGM. This is a winning team, a winning technology, a winning market opportunity, and has the potential to impact millions of lives.”



Other investors include [RRE Ventures](#), [First Round Capital](#), [M. Night Shyamalan](#), [Tony Fadell](#)

## Our Team



**Jeff Dachis** Founder and CEO

A proven track record of successful entrepreneurship and disruptive innovation and over a decade of experience in digital design and the diabetes industry



**Jon Brilliant** CFO

Proven track record developing and launching diabetes devices



**Dan Goldner** EVP Research & Development

Proven expertise in data science, machine learning, and AI



**Brian Kemper** EVP Product & Programs

15+ years in medical devices and digital solutions

# One Health: Make sense of your health



**one health**

Make Sense of Your Health

one health

## The Opportunity

### Next Generation Health Sensing Experience

designed to revolutionize the CGM market with a device purpose built for people with Type 2 diabetes, 95% of whom are unserved by CGM today

### Enabled By AI Proven to Improve Health Outcomes

made possible >60 billion real-time, contextual data points fueling first-to-market predictions

### Made Possible with Proprietary Technology

integrating a micro-needle based sensing platform with personalized AI to deliver continuous sensing and continuous insight

### Unlocking Broad Payor Coverage & Reimbursement

with a low cost daily disposable sensor that reduces starting price point for CGMs by up to 90%

### Maximizing Adoption and Winning in Type 2 Diabetes

with a low cost, no commitment CGM experience purpose built to deliver access, affordability, and outcomes for people with Type 2 Diabetes

Device shown is under development and subject to FDA clearance or approval. Future Projections Not Guaranteed

2 | PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.




## A Next Generation Health Sensing Experience



Durable Applicator

Durable Battery + Transmitter





**Built On A Micro-Needle Based Platform with Multi-Modal Sensing Capabilities**

**Optical and Electronic Sensing Capabilities:**


- Blood Pressure<sup>1</sup>
- + Activity<sup>1</sup>
- + EKG<sup>1</sup>
- + Sleep<sup>1</sup>

**Micro-Needle Based Sensing Capabilities:**

- Glucose<sup>2</sup>**  
For diabetes, pre-diabetes, obesity, consumer wellness...
- Lactic Acid<sup>3</sup>**  
For performance athletics, consumer wellness...
- Urea<sup>4</sup>**  
For chronic kidney disease

1. Under development and subject to FDA clearance or approval  
 2. Early in development, clinical validation in progress  
 3. Pre-clinical proof-of-concept complete  
 4. In-house proof-of-concept complete


one health



**The CGM Market Has Experienced Explosive Growth Over the Past 10 Years**

There were >8M CGM users globally generating ~\$10Bn in CGM revenue      The market is dominated by two large players with similar 10-14 day      The existing CGM paradigm leaves >90% of people with T2D unserved

in 2023



PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH DISEASING INC.


devices at comparable price points

FreeStyle Libre 2 5.5M Users \$1.4Bn Q4'23 Revenue

DEXCOM 2.3M Users \$1Bn Q4'23 Revenue



and is ripe for disruption



one health

### Meet Jim...

Jim has Type 2 Diabetes and does not want to start using insulin. He is willing to adjust his lifestyle to get his A1C under control but needs some help getting started.

His doctor suggests starting on a CGM. This will help Jim understand what impacts his blood sugar and make the right decisions to improve his health.

Jim's insurance does not reimburse for CGM. He wants to know how much will this cost?



### High Costs Make CGM Uncovered and Unaffordable For Most People with Type 2 Diabetes



Fully disposable every 14 days. Sensor price includes the fixed costs of a new applicator, battery, and transmitter for each wear

#### The Numbers<sup>1</sup>

- 12 Applicators
- 12 Batteries
- 12 Bluetooth Transmitters
- 12+ Sensors

Day 1 Cost = \$70

Lowest Annual Cost<sup>1</sup> = \$840

- ✗ Not reimbursed by insurance
- ✗ Not affordable out-of-pocket

<sup>1</sup> Assumes at least one sensor a month

PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH DISEASING INC.

one health

to get his A1C under control but needs some help getting started.



**His doctor suggests starting on a CGM.** This will help Jim understand what impacts his blood sugar and make the right decisions to improve his health.

Jim's insurance does not reimburse for CGM. He wants to know **how much will this cost?**



## High Costs Make CGM Uncovered and Unaffordable For Most People with Type 2 Diabetes



Fully disposable every 14 days. Sensor price includes the fixed costs of a new applicator, battery, and transmitter for each wear.

### The Numbers<sup>1</sup>

- 12 Applicators
- 12 Batteries
- 12 Bluetooth Transmitters
- 12+ Sensors

**Day 1 Cost = \$70**

**Lowest Annual Cost<sup>1</sup> = \$840**

- ✗ Not reimbursed by insurance
- ✗ Not affordable out-of-pocket

<sup>1</sup> Assumes at least one sensor a month.

© PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSCIENCE INC.

one health

one health



- ✓ Reimbursable for all patient segments
- ✓ Affordable at \$5 a day

<sup>1</sup> Assumes at least one sensor a month.

© PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSCIENCE INC.

one health

When One Health is manufactured, we predict it will be the lowest cost CGM on the market

*Future projections are not guaranteed.*

## One Health is the Cost Effective and Reimbursable CGM Choice

| Diagnosis:<br>3 CGM days per month | GLP-1 Companion:<br>5 CGM days per month | T2 Uncontrolled:<br>7 CGM days per month | Insulin-Management:<br>24/7/365 CGM |
|------------------------------------|--|--|-------------------------------------|
| 1.2M people per year (U.S.)        | 15.5M people (U.S.) <sup>1</sup>         |  | ~5M people (U.S.) <sup>1</sup>      |

one health

**\$5 per sensor**  
No commitment

|  |              |              |                |
|--|--------------|--------------|----------------|
| \$15 / month   | \$25 / month | \$35 / month | \$1,825 / year |
| ▲ Daily wear flexibility supports a variable cost model, enabling payors to find a reimbursable use case for each T2 patient segment |              |              |                |

dexcom

**\$60 per sensor**

|  |              |              |                |
|--|--------------|--------------|----------------|
| ▼ High fixed costs make broad T2 reimbursement financially untenable for most payors |              |              |                |
| \$60 / month   | \$60 / month | \$60 / month | \$7,190 / year |

10 day commitment

\$70 / month

\$70 / month

\$70 / month

\$1,825 / year

FreeStyle Libre 2

\$70 per sensor

14 day commitment


1. IIR Health Tracking, Feb/Apr/May 1, 2020

2. PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING, INC.

one health

## Improving Health Outcomes with Personalized AI, Even on Non-CGM Days

Immense data wealth and AI capabilities to inform action and improve outcomes, enabling the class effect of CGM even on days when a sensor is not being worn



### Proven Results<sup>3</sup>



**35 min**  
Additional activity per week!



**4.7x**  
lower risk of depression<sup>3</sup>



**20g**  
Fewer carbs per meal!



**21 mm Hg**  
reduction in systolic blood pressure<sup>4</sup>



**1.9%**  
Reduction in eA1c in 3 months<sup>1,2</sup>



**10.4lbs**  
reduction in weight<sup>5</sup>

1. Ozkan C, Hayman M, Husabain R, van Erkel R, Redford D, Dachtel J. The One Drop Mobile App with 14-Day Changing Interval FreeStyle Libre and Self-worn Diabetes (ADA Abstract Book, 2017,2018) 14478

2. Ozkan C, Hayman M, van Erkel R, Dachtel J. The One Drop Mobile App and Experts Program is Evidence-based and Improves Blood Glucose. Am Behav Mac (S3) Abstract Book, 2017,2018) 133-5389

3. Saini S, Gohain S, Nagar M, Madhavan B, Prasad K, Ghosh S, Datta J. One Drop Digital App and Coaching Improves Lifestyle Risk, Glycemic Control and Psychological Well-being in People with Type 2 Diabetes. Circulation 2020;141:1499

4. Saini S, Hsu R, Nagar M, Prasad K, Prasad A, Ghosh S, Madhavan B, Prasad K, Ghosh S, Datta J. One Drop's Multipurpose Program is Associated with Blood Pressure Reduction in Employees with High Blood Pressure and Maintenance for Employees with Blood Pressure in Range. Circulation 2021;144:1370

5. Ozkan C, Hayman M, Husabain R, Redford D, Dachtel J. One Drop improves KID among people with type 2 diabetes. Ann Behav Med 2019;53(4):356

2. PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING, INC.

one health

## Delivering A Premium User Experience That Embodies Next-Gen Sensibilities

Pain-free, needle free application breaks down barriers to adoption and adherence



Multi-modal sensing capabilities with electrical and optical sensors integrated into transmitter



A design-forward consumer grade experience that feels anything but clinical



Reduced carbon footprint with reusable elements and limited use of single-use plastics




2. PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING, INC.

one health


Uniquely enabled by  
set of capabilities

including proprietary  
micro-needle based  
sensing technology

and AI fueled by  
unprecedented data  
wealth



### Patented Micro-Needle Based Sensing Platform Ten Years in the Making



One Health's proprietary micro-needle design and application is an engineering breakthrough that makes micro-needle based sensing possible

**Proprietary dicing technique** delivers clean, durable needle shape

**Silicon oxide insulation** reduces interference for accurate sensing

**Controlled application** ensures effective contact with minimal adverse events

**Polymers specifically chosen** to provide selectivity

**Wafer-scale manufacture** provides path for continued cost reduction

one health

### Unparalleled Cost Leadership Enabled by Unique Engineering Capabilities



**Disposable micro-needle sensors built on silicon wafers enable continued COGs reduction**



**Automation**  
13% improvement in yield



**Increase Wafer Size**  
1.9x increase in die per wafer going from a 6 to 8 inch wafer.



**Decrease Array Size**  
2.5x increase in die per wafer when decreasing from a 5x5 to 3x3 array

**Durable components can be reused across multiple wears**

Includes the battery and bluetooth transmitter as well as optical and electronic sensing components

Reusable for two years, allowing the cost to be amortized over many wears

**Cost-effective scaling with minimal capital expenditure requirements**

Micro-needle sensors built on silicon wafers allow us to leverage existing silicon wafer manufacturing infrastructure

Minimal capital and operating expenses required

Chemistry and biological materials are integrated onto semiconductor chip manufacturing to rapidly produce low-cost sensors

one health

### Personalized AI Powered By Unprecedented Biometric Data Wealth

Over 60bn real-time,



AI Blood



AI Blood




AI Weight



AI BGM Outcomes


**contextual data points collected to date<sup>1</sup> and fueling first-to-market predictions**



<sup>1</sup> One Health has a non-proprietary, open-source license to all management user data collected by Informet Data Systems Inc. (65%) One Drop from inception through March 2024.  
<sup>2</sup> Algorithm development involves pending medication product.  
<sup>3</sup> Brink MD, et al. Sclafani J, Looptan M, Hey-Roos J, Dackiw J, Sears L. Effects of a Novel Blood Glucose Forecasting Feature on Glycemic Management and Logging in Adults With Type 2 Diabetes Using One Drop. *Diabetes Care*. 2022;75(10):2402.  
 © PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.

one health

**One Health CGM Functionality Has Been Successfully Demonstrated in Clinic**



<sup>1</sup> Actual MARDs will be based on sensor blood draw and final prospective algorithm.  
 © PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.

**1,656 hours of on-body clinical data collected to date**

198,720 data points from 69 wears on 39 people under IRB-approved protocol

**Estimated MARD < 10**

Based on correlation with 7,131 reference CGM data points.<sup>1</sup>

**24-hour wear confirmed**

Successful skin adhesion, data transmission, and battery life

**Demonstrated safety & tolerability**

Zero instances of serious adverse events or instances of papules, edema or vesicular eruptions

**510(k) pathway validated by FDA**

Regulatory pathway and predicate device validated by the FDA through the pre-submission process

<sup>1</sup>FDA Clearance Not Guaranteed

one health

**One Health Intellectual Property**

54 Issued Patents ● 41 Pending or Allowed Applications<sup>1</sup> ● 7 Licensed Applications<sup>2</sup>

**Wearable Sensing Systems**

**Wearable Sensors, Applicators, Software**

US10,595,754 (8008.US00); US11,172,851<sup>1</sup> (8008.US02); US11,357,430 (8008.US03); US11,317,222 (8008.US07); US11,291,390 (8002.US08); US11,272,866 (8002.US09); US11,272,865 (8005.S900)  
 US17,256,753 (8016.US03); CA3,180,804 (8016.CA00); EP2172796.1 (8016.EP00); US16,751,518 (8008.US01); US17,728,893 (8008.US06); US18,130,873 (8008.US08); US17,667,530 (8021.US01); US17,650,673 (8002.US10); US17,650,689 (8002.US11); US17,681,689 (8002.US12); 17/681,681 (8002.US13)

**Cloud Platform**


US17,156,820 (8002.US08); US17,236,753 (8001.US03); CA3,180,804 (8016.CA00); EP2172796.1 (8016.EP00)

**Designs**

**Sensor Device, Applicator, Charging Station**

US 10,824,054 (8001.US00); US 10,820,988 (8002.US00); EP 8752245.1-1 (8023.EP05); EP 0101; AU202116504 (8023.AU01); AU202116505 (8024.AU02); AU202116506 (8025.AU03); GB2107057 - GB2107059 (8023.GB00-GB02); GB2107060 - GB2107063 (8024.GB00-GB03); GB2107064 - GB2107067 (8025.GB00-GB03); 8023.JP00 - 8023.JP02; 8024.JP00 - 8024.JP02; 8025.JP00-8025.JP02; KR20-2021-49924 to KR30-2021-49926 (8023.KR00 - 8025.KR03); US20210692038.7 (8023.US00); US29/779,914 (8025.US00); CA, CN (8023); CN202130692038.7 (8024.CN01); CN20210692038.2 (8025.CN02)

<sup>1</sup> US of February 2, 2024  
<sup>2</sup> Appears in filing more than once due to scope of application or issued patent  
<sup>3</sup> Licensed from Informet Data Systems Inc. (65% One Drop)  
 © PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.



**Advanced Analytics & Algorithms**

**Food Logger**

US18,107,933 (8027.US01)

**Continuous Blood Glucose Monitoring (CGM)**

US18,285,363<sup>1</sup> (8013.US02); AU, CA, EP, JP, KR, CN (8013)

**Blood Pressure Predictions**

US17,744,444 (8026.US01)

**Forecasting Blood Glucose Concentration**

US16,958,858 (8012.US02); AU, CA, EP, JP, KR, CN (8012)

**Forecasting of Metabolic Health Metrics/Goals**

US17,162,795 (8014.US01)

**Hypoglycemia Prediction**

US18,285,363<sup>1</sup> (8013.US02); AU, CA, EP, JP, KR, CN (8013)

**Predictive Guidance Systems for Personalized Health**


US18,528,767 (8017.US02)

**Adaptive Healthcare Support and Behavioral Intervention**

US17,388,584 (8018.US01); US18,393,635 (8018.US02)


one health

## Clear Path to FDA Submission and Launch in Two Years



*Future projections are not guaranteed*

## Use of Proceeds Will Enable One Health to Reach A Meaningful Value Inflection Point



*Future projections are not guaranteed*

## Launching in 2026 with \$250M in Revenue 2 Years Post Launch \*Future Projections Not Guaranteed

**2028 \$250M**

230K U.S. Users  
3% Share of U.S. Market  
45% Gross Margin

**2031 \$1Bn**


980K U.S. Users  
9% Share of U.S. Market  
60% Gross Margin

**A Highly Differentiated Positioning Enables Rapid Uptake**

Achieving T2D adoption by enabling a flexible pricing structure and reimbursable cost profile.

**Delivering Continued Gross Margin Expansion**

Scaling efficiencies across multiple levers including automation, scale, silicon wafer size, and size of micro-needle array.



## A Seasoned Leadership Team With Deep Experience and Proven Success and Abilities to Execute



**Jeff Dachis, MA**  
Chairman, CEO and Founder

### A Track Record of Successful Entrepreneurship and Disruptive Innovation

**razorfish**

- Co-Founder and CEO
- \$55M IPO
- \$6B sale to Microsoft
- \$2B annual revenue today



- Chairman, CEO and Founder
- >\$100M raised
- >1.5M registered users
- >\$50M revenue in 2021



**Jon Brilliant, BS, JD**  
CFO

Proven track record developing and launching diabetes devices



**Dan Goldner, M.Ed., Ph.D**

Research & Development  
Proven expertise in data science, machine learning, and AI



**Brian Kemper**

Product & Programs  
15+ years in medical devices and digital solutions



one health

## The Opportunity

### AI -Enabled CGM Purpose Built to Win in Type 2 Diabetes

#### Enabled by Proprietary Technology

Integrating a micro-needle based sensing platform with personalized AI proven to improve health outcomes

#### High Growth With Favorable Economics

projecting \$250M of revenue in 2028 and a clear path to continued margin expansion

#### Designed To Unlock Payor Coverage

eliminating existing barriers to access with the lowest cost profile and greatest use case flexibility

#### Future Proofed Platform Technology

poised to extend rapidly beyond glucose and beyond diabetes.

#### Near-Term Catalysts

with commercially viable performance data expected in less than 12 months

Device shown is under development and subject to FDA clearance or approval

25 | PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.

one health

one health

